bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Data from Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study
Authors: Dubois Sydney , Viailly Pierre-Julien , Mareschal Sylvain , Bohers Elodie , Bertrand Philippe , Ruminy Philippe , Maingonnat Catherine , Jais Jean-Philippe , Peyrouze Pauline , Figeac Martin , Molina Thierry J. , Desmots Fabienne , Fest Thierry , Haioun Corinne , Lamy Thierry , Copie-Bergman Christiane , Brière Josette , Petrella Tony , Canioni Danielle , Fabiani Bettina , Coiffier Bertrand , Delarue Richard , Peyrade Frédéric , Bosly André , André Marc , Ketterer Nicolas , Salles Gilles , Tilly Hervé , Leroy Karen , Jardin Fabrice
Published: April 2023

Supplementary methods, figures, and tables Figure S1: Variant filters applied to Lymphopanel NGS data. Figure S2: Validation of variants according to SIFT and CADD scores. Figure S3: PMBL samples harbor more mutations than other DLBCL subtypes. Figure S4: Role of AID-induced SHM in DLBCL. Figure S5: Mutation frequency by subtype. Figure S6: Clustering of gene mutations according to subtype. Figure S7: Protein representations of observed mutations. Figure S8: Correlations between age and specific gene mutations. Figure S9: Prognosis according to IPI and subtype. Figure S10: Prognostic impact of gene mutations among the Lymphopanel. Table S1: Clinical characteristics of patients in our cohort. Table S2: Overview of the Lymphopanel used for NGS analysis. Table S3: Overview of pathway selection Table S4: Validation of variant filtering by an independent study of seven non-tumoral samples from DLBCL patients Table S5: Validated variants. Table S6: Lymphopanel NGS detection of genes with high AID target frequencies. Table S7: Prognostic impact of mutations in Lymphopanel genes
Supplementary Table 1 from PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients
Authors: Kakavand Hojabr , Wilmott James S. , Menzies Alexander M. , Vilain Ricardo , Haydu Lauren E. , Yearley Jennifer H. , Thompson John F. , Kefford Richard F. , Hersey Peter , Long Georgina V. , Scolyer Richard A.
Published: April 2023

Supplementary Table 1. Patterns of PD-L1 staining at various time points of MAPK inhibitor treatment (n=55 PD-L1 positive patients).
Supplementary Figure 2 from PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients
Authors: Kakavand Hojabr , Wilmott James S. , Menzies Alexander M. , Vilain Ricardo , Haydu Lauren E. , Yearley Jennifer H. , Thompson John F. , Kefford Richard F. , Hersey Peter , Long Georgina V. , Scolyer Richard A.
Published: April 2023

Supplementary Figure 2. LAG3 and FoxP3 expressing lymphocytes at PRE, EDT and PROG. Patients treated with either BRAFi (A-B) or Combi (C-D) showed no significant changes in LAG3+ and FoxP3+ lymphocytes at any time point.
Supplementary Tables S1 and S2 from Genomic Analysis of Metastatic Cutaneous Squamous Cell Carcinoma
Authors: Li Yvonne Y. , Hanna Glenn J. , Laga Alvaro C. , Haddad Robert I. , Lorch Jochen H. , Hammerman Peter S.
Published: April 2023

Supplementary Tables S1 and S2. Supplementary Table S1. List of SNVs and indels identified in the 29 metastatic cSCC samples. Supplementary Table S2. List of CNVs identified in the 29 metastatic cSCC samples.
Supp Figure 2 from Genomic Analysis of Metastatic Cutaneous Squamous Cell Carcinoma
Authors: Li Yvonne Y. , Hanna Glenn J. , Laga Alvaro C. , Haddad Robert I. , Lorch Jochen H. , Hammerman Peter S.
Published: April 2023

Supplementary Figure 2 - Alterations in RTK/RAS/PI3K pathway and chromatin remodeling genes associated with overall survival (OS) in metastatic cSCC.
Supp Figure 1 from Genomic Analysis of Metastatic Cutaneous Squamous Cell Carcinoma
Authors: Li Yvonne Y. , Hanna Glenn J. , Laga Alvaro C. , Haddad Robert I. , Lorch Jochen H. , Hammerman Peter S.
Published: April 2023

Supplementary Figure 1 - ARID5B and CARD11 alterations associated with PFS in metastatic cSCC.
Video 5 from In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell–Mediated Tumor Killing
Authors: Lehmann Steffi , Perera Ramanil , Grimm Hans-Peter , Sam Johannes , Colombetti Sara , Fauti Tanja , Fahrni Linda , Schaller Teilo , Freimoser-Grundschober Anne , Zielonka Jörg , Stoma Szymon , Rudin Markus , Klein Christian , Umana Pablo , Gerdes Christian , Bacac Marina
Published: April 2023

2P time-lapse acquisition of LS174T / human PBMC cografts on day 4 after implantation (baseline), 24 h after control and 24 h after CEA TCB treatment. LS174T RFP tumor cells (red), CFSE labeled T-cells (green). Scale bar indicates 50 ÃŽÂ¼m.
Supplemental Figure 3c from PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance
Authors: Stern Howard M. , Gardner Humphrey , Burzykowski Tomasz , Elatre Wafaa , O'Brien Carol , Lackner Mark R. , Pestano Gary A. , Santiago Angela , Villalobos Ivonne , Eiermann Wolfgang , Pienkowski Tadeusz , Martin Miguel , Robert Nicholas , Crown John , Nuciforo Paolo , Bee Valerie , Mackey John , Slamon Dennis J. , Press Michael F.
Published: April 2023

Supplemental Figure 3c. Comparison of western immunoblot results and PTEN IHC in EFM-19, CAMA-1, MDA-MB-415, MFM-223, HCC-1569, EFM192A, KPL-1, and BT549 human breast cancer cell lines.
Supplemental Methods from A Supplemented High-Fat Low-Carbohydrate Diet for the Treatment of Glioblastoma
Authors: Martuscello Regina T. , Vedam-Mai Vinata , McCarthy David J. , Schmoll Michael E. , Jundi Musa A. , Louviere Christopher D. , Griffith Benjamin G. , Skinner Colby L. , Suslov Oleg , Deleyrolle Loic P. , Reynolds Brent A.
Published: April 2023

Detailed and expanded methods on cell lines, in-vitro assays, in-vivo transplants, diet creation, diet induction timelines, ex-vivo analyses and bench assays for all data presented.
Supplemental Figure 4 from A Supplemented High-Fat Low-Carbohydrate Diet for the Treatment of Glioblastoma
Authors: Martuscello Regina T. , Vedam-Mai Vinata , McCarthy David J. , Schmoll Michael E. , Jundi Musa A. , Louviere Christopher D. , Griffith Benjamin G. , Skinner Colby L. , Suslov Oleg , Deleyrolle Loic P. , Reynolds Brent A.
Published: April 2023

The sHFLC diet increases survival and reduces tumor burden in second patient-derived glioblastoma stem cell line.
Supplementary Figure S5 from Activation of Vitamin D Receptor Signaling Downregulates the Expression of Nuclear FOXM1 Protein and Suppresses Pancreatic Cancer Cell Stemness
Authors: Li Zhiwei , Jia Zhiliang , Gao Yong , Xie Dacheng , Wei Daoyan , Cui Jiujie , Mishra Lopa , Huang Suyun , Zhang Yanqiao , Xie Keping
Published: April 2023

Supplementary Figure S5. Impact of altered VDR signaling on PDAC cell migration and invasion in vitro
Supplementary Figure 5 from Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma
Authors: Di Stefano Anna Luisa , Fucci Alessandra , Frattini Veronique , Labussiere Marianne , Mokhtari Karima , Zoppoli Pietro , Marie Yannick , Bruno Aurelie , Boisselier Blandine , Giry Marine , Savatovsky Julien , Touat Mehdi , Belaid Hayat , Kamoun Aurelie , Idbaih Ahmed , Houillier Caroline , Luo Feng R. , Soria Jean-Charles , Tabernero Josep , Eoli Marica , Paterra Rosina , Yip Stephen , Petrecca Kevin , Chan Jennifer A. , Finocchiaro Gaetano , Lasorella Anna , Sanson Marc , Iavarone Antonio
Published: April 2023

Supplementary Figure 5. PFS and OS of FGFR3-TACC3-positive glioma patients.
Supplementary Figure S3 from Activation of Vitamin D Receptor Signaling Downregulates the Expression of Nuclear FOXM1 Protein and Suppresses Pancreatic Cancer Cell Stemness
Authors: Li Zhiwei , Jia Zhiliang , Gao Yong , Xie Dacheng , Wei Daoyan , Cui Jiujie , Mishra Lopa , Huang Suyun , Zhang Yanqiao , Xie Keping
Published: April 2023

Supplementary Figure S3. Regulation of ÃŽÂ²-catenin expression by FOXM1 in PDAC cells
Supplementary Figure Legends from Activation of Vitamin D Receptor Signaling Downregulates the Expression of Nuclear FOXM1 Protein and Suppresses Pancreatic Cancer Cell Stemness
Authors: Li Zhiwei , Jia Zhiliang , Gao Yong , Xie Dacheng , Wei Daoyan , Cui Jiujie , Mishra Lopa , Huang Suyun , Zhang Yanqiao , Xie Keping
Published: April 2023

Supplementary Figure Legends for 7 figures
Supplemental table 1 from Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients
Authors: Yaeger Rona , Cercek Andrea , O'Reilly Eileen M. , Reidy Diane L. , Kemeny Nancy , Wolinsky Tamar , Capanu Marinela , Gollub Marc J. , Rosen Neal , Berger Michael F. , Lacouture Mario E. , Vakiani Efsevia , Saltz Leonard B.
Published: April 2023

Supplemental table 1. Genes included in custom next-generation sequencing assay.
Supplementary Tables S1-6 from Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma
Authors: Agelopoulos Konstantin , Richter Günther H.S. , Schmidt Eva , Dirksen Uta , von Heyking Kristina , Moser Benjamin , Klein Hans-Ulrich , Kontny Udo , Dugas Martin , Poos Kathrin , Korsching Eberhard , Buch Thorsten , Weckesser Matthias , Schulze Isabell , Besoke Regina , Witten Anika , Stoll Monika , Köhler Gabriele , Hartmann Wolfgang , Wardelmann Eva , Rossig Claudia , Baumhoer Daniel , Jürgens Heribert , Burdach Stefan , Berdel Wolfgang E. , Müller-Tidow Carsten
Published: April 2023

Supplementary Tables S1-6. Table S1: Validation of somatic mutations by Sanger sequencing for construction of ROC Table S2: Characteristics of the discovery data set for exome sequencing Table S3: Somatic mutations in the discovery data set (filtered with MutSigCV1.6) Table S4: Recurrent non-synonymous mutations (filtered with MutSigCV1.6) Table S5: Characteristics of the expression data set. Table S6 : Shared mutations in consecutive sarcomas
Supplementary Materials from Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma
Authors: Agelopoulos Konstantin , Richter Günther H.S. , Schmidt Eva , Dirksen Uta , von Heyking Kristina , Moser Benjamin , Klein Hans-Ulrich , Kontny Udo , Dugas Martin , Poos Kathrin , Korsching Eberhard , Buch Thorsten , Weckesser Matthias , Schulze Isabell , Besoke Regina , Witten Anika , Stoll Monika , Köhler Gabriele , Hartmann Wolfgang , Wardelmann Eva , Rossig Claudia , Baumhoer Daniel , Jürgens Heribert , Burdach Stefan , Berdel Wolfgang E. , Müller-Tidow Carsten
Published: April 2023

Supplementary Materials. Additional Material and Methods section and clinical data of the Ponatib treated patient.
Supplementary figure 5 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
Authors: van Gool Inge C. , Eggink Florine A. , Freeman-Mills Luke , Stelloo Ellen , Marchi Emanuele , de Bruyn Marco , Palles Claire , Nout Remi A. , de Kroon Cor D. , Osse Elisabeth M. , Klenerman Paul , Creutzberg Carien L. , Tomlinson Ian P.M. , Smit Vincent T.H.B.M. , Nijman Hans W. , Bosse Tjalling , Church David N.
Published: April 2023

Supplementary figure 5. Expression of T cell markers and cytotoxic effectors by EC molecular subtype
Supplementary figure legend from RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
Authors: Loi Sherene , Dushyanthen Sathana , Beavis Paul A. , Salgado Roberto , Denkert Carsten , Savas Peter , Combs Susan , Rimm David L. , Giltnane Jennifer M. , Estrada Monica V. , Sánchez Violeta , Sanders Melinda E. , Cook Rebecca S. , Pilkinton Mark A. , Mallal Simon A. , Wang Kai , Miller Vincent A. , Stephens Phil J. , Yelensky Roman , Doimi Franco D. , Gómez Henry , Ryzhov Sergey V. , Darcy Phillip K. , Arteaga Carlos L. , Balko Justin M.
Published: April 2023

Supplementary figure legend
Supplementary Table S1 from Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer
Authors: Janni Wolfgang J. , Rack Brigitte , Terstappen Leon W.M.M. , Pierga Jean-Yves , Taran Florin-Andrei , Fehm Tanja , Hall Carolyn , de Groot Marco R. , Bidard François-Clement , Friedl Thomas W.P. , Fasching Peter A. , Brucker Sara Y. , Pantel Klaus , Lucci Anthony
Published: April 2023

Table S1. Patients and study variables according to study center for the pooled analysis of circulating tumor cells in early breast cancer
Supplementary Figure S2A from Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer
Authors: Janni Wolfgang J. , Rack Brigitte , Terstappen Leon W.M.M. , Pierga Jean-Yves , Taran Florin-Andrei , Fehm Tanja , Hall Carolyn , de Groot Marco R. , Bidard François-Clement , Friedl Thomas W.P. , Fasching Peter A. , Brucker Sara Y. , Pantel Klaus , Lucci Anthony
Published: April 2023

Figure S2. Hazard ratios (black line) and 95% confidence intervals (blue area) from the univariate survival analyses according to the presence of CTCs categorized using different cutoff values (e.g., cutoff 0: 0 CTCs vs. > 0; cutoff 1: 0-1 CTCs vs. > 1; cutoff 2: 0-2 CTCs vs. > 2). Panel A shows breast-cancer-specific survival, and Panel B shows distant disease-free survival.
Supplementary Figure S2. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus
Authors: Jenkinson Claire , Elliott Victoria L. , Evans Anthony , Oldfield Lucy , Jenkins Rosalind E. , O'Brien Darragh P. , Apostolidou Sophia , Gentry-Maharaj Aleksandra , Fourkala Evangelia-O , Jacobs Ian J. , Menon Usha , Cox Trevor , Campbell Fiona , Pereira Stephen P. , Tuveson David A. , Park B. Kevin , Greenhalf William , Sutton Robert , Timms John F. , Neoptolemos John P. , Costello Eithne
Published: April 2023

Detection of thrombospondin 1 (TSP-1) by MRM in resectable PDAC cases versus advanced PDAC cases
Supplementary Table 4 from A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer
Authors: Adjei Alex A. , Richards Donald A. , El-Khoueiry Anthony , Braiteh Fadi , Becerra Carlos H.R. , Stephenson Joe J. , Hezel Aram F. , Sherman Morris , Garbo Lawrence , Leffingwell Diane P. , Iverson Cory , Miner Jeffrey N. , Shen Zancong , Yeh Li-Tain , Gunawan Sonny , Wilson David M. , Manhard Kimberly J. , Rajagopalan Prabhu , Krissel Heiko , Clendeninn Neil J.
Published: April 2023

Refametinib geometric mean (% coefficient of variation) single-dose pharmacokinetic data on day 1 of course 1
Supplementary Figures 1-6 from Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer
Authors: Gonzalez-Villasana Vianey , Fuentes-Mattei Enrique , Ivan Cristina , Dalton Heather J. , Rodriguez-Aguayo Cristian , Fernandez-de Thomas Ricardo J. , Aslan Burcu , del C. Monroig Paloma , Velazquez-Torres Guermarie , Previs Rebecca A. , Pradeep Sunila , Kahraman Nermin , Wang Huamin , Kanlikilicer Pinar , Ozpolat Bulent , Calin George , Sood Anil K. , Lopez-Berestein Gabriel
Published: April 2023

Supplementary Figures 1-6. Supplementary Figure S1: In vivo and in vitro effects of ZA on apoptosis. Supplementary Figure S2: Nab-paclitaxel inhibits tube formation.Supplementary Figure S3: RPPA analysis in HeyA8 MDR treated with ZA. Supplementary Figure S4: Functional changes induced by ZA in HeyA8 MDR. Supplementary Figure S5: ZA decreases angiogenic factors. Supplementary Figure S6: ZA inhibits cell invasion
Supplementary Figure 1 from Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma
Authors: Chau Nicole G. , Li Yvonne Y. , Jo Vickie Y. , Rabinowits Guilherme , Lorch Jochen H. , Tishler Roy B. , Margalit Danielle N. , Schoenfeld Jonathan D. , Annino Don J. , Goguen Laura A. , Thomas Tom , Becker Hailey , Haddad Tyler , Krane Jeffrey F. , Lindeman Neal I. , Shapiro Geoffrey I. , Haddad Robert I. , Hammerman Peter S.
Published: April 2023

Correlation with Number of Alterations per Sample and Progression-Free Survival.
Supplementary Tables 1-3 from A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent
Authors: Appleman Leonard J. , Balasubramaniam Sanjeeve , Parise Robert A. , Bryla Christine , Redon Christophe E. , Nakamura Asako J. , Bonner William M. , Wright John J. , Piekarz Richard , Kohler David R. , Jiang Yixing , Belani Chandra P. , Eiseman Julie , Chu Edward , Beumer Jan H. , Bates Susan E.
Published: April 2023

Supplementary Tables 1-3. Supplemental Table 1. Plasma pharmacokinetics of DMS612 metabolites. Supplemental Table 2. Pharmacodynamic assessment of !-H2AX detection in PBMCs. Mean values for !-H2AX foci per cell with DMS612 doses of 1.5, 3, 5, 7, 9 and 12 mg/m2 at the indicated time in hours (h). Supplemental Table 3. Pharmacodynamic assessment of !-H2AX detection in hair follicles. Mean values for cell with more than 4 !-H2AX foci per cell in plucked scalp hairs with DMS612 doses of 1.5, 3 and 9 mg/m2 at the indicated time in hours (h).
Supplemental Data 5 from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
Authors: Lambertz Irina , Kumps Candy , Claeys Shana , Lindner Sven , Beckers Anneleen , Janssens Els , Carter Daniel R. , Cazes Alex , Cheung Belamy B. , De Mariano Marilena , De Bondt An , De Brouwer Sara , Delattre Olivier , Gibbons Jay , Janoueix-Lerosey Isabelle , Laureys Geneviève , Liang Chris , Marchall Glenn M. , Porcu Michael , Takita Junko , Trujillo David Camacho , Van Den Wyngaert Ilse , Van Roy Nadine , Van Goethem Alan , Van Maerken Tom , Zabrocki Piotr , Cools Jan , Schulte Johannes H. , Vialard Jorge , Speleman Frank , De Preter Katleen
Published: April 2023

Supplemental data 5: Differential expression analysis upon ALK inhibition
Supplemental Table S4 from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Authors: Tobin Nicholas P. , Wennmalm Kristian , Lindström Linda S. , Foukakis Theodoros , He Liqun , Genové Guillem , Östman Arne , Landberg Göran , Betsholtz Christer , Bergh Jonas
Published: April 2023

Multivariate evaluation of prognostic markers in endocrine-treated patients characterized by low genomic grade
Supplementary Tables 1-2 from PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity
Authors: Incio Joao , Tam Josh , Rahbari Nuh N. , Suboj Priya , McManus Dan T. , Chin Shan M. , Vardam Trupti D. , Batista Ana , Babykutty Suboj , Jung Keehoon , Khachatryan Anna , Hato Tai , Ligibel Jennifer A. , Krop Ian E. , Puchner Stefan B. , Schlett Christopher L. , Hoffmman Udo , Ancukiewicz Marek , Shibuya Masabumi , Carmeliet Peter , Soares Raquel , Duda Dan G. , Jain Rakesh K. , Fukumura Dai
Published: April 2023

Supplementary Table 1: Protein quantification of cytokines in tumors and plasma of WT and Flt1TK-/- obese using ELISA; Supplementary Table 2: Quantification of the expression of IL-1ÃƒÅ½Ã,Â² and VEGFR-1 in TAMs from PAN02 tumors by mmunofluorescence.
Supplementary Figures 7-8 from PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity
Authors: Incio Joao , Tam Josh , Rahbari Nuh N. , Suboj Priya , McManus Dan T. , Chin Shan M. , Vardam Trupti D. , Batista Ana , Babykutty Suboj , Jung Keehoon , Khachatryan Anna , Hato Tai , Ligibel Jennifer A. , Krop Ian E. , Puchner Stefan B. , Schlett Christopher L. , Hoffmman Udo , Ancukiewicz Marek , Shibuya Masabumi , Carmeliet Peter , Soares Raquel , Duda Dan G. , Jain Rakesh K. , Fukumura Dai
Published: April 2023

Supplementary Figure 7 - Effects of VEGFR-1 signaling ablation on IGF-1R/IR signaling pathways in PAN02 and E0771 tumors implanted in obese mice; Supplementary Figure 8 - Additional effects of VEGFR-1 signaling ablation and metformin on tumor metabolism and vessel density in obese mice.
Supplementary Figure 9 from PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity
Authors: Incio Joao , Tam Josh , Rahbari Nuh N. , Suboj Priya , McManus Dan T. , Chin Shan M. , Vardam Trupti D. , Batista Ana , Babykutty Suboj , Jung Keehoon , Khachatryan Anna , Hato Tai , Ligibel Jennifer A. , Krop Ian E. , Puchner Stefan B. , Schlett Christopher L. , Hoffmman Udo , Ancukiewicz Marek , Shibuya Masabumi , Carmeliet Peter , Soares Raquel , Duda Dan G. , Jain Rakesh K. , Fukumura Dai
Published: April 2023

Effects of VEGFR-1 signaling ablation on E0771 tumor growth, vascular and immune environment in lean and obese mice.
Supplementary Figure 4 from PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity
Authors: Incio Joao , Tam Josh , Rahbari Nuh N. , Suboj Priya , McManus Dan T. , Chin Shan M. , Vardam Trupti D. , Batista Ana , Babykutty Suboj , Jung Keehoon , Khachatryan Anna , Hato Tai , Ligibel Jennifer A. , Krop Ian E. , Puchner Stefan B. , Schlett Christopher L. , Hoffmman Udo , Ancukiewicz Marek , Shibuya Masabumi , Carmeliet Peter , Soares Raquel , Duda Dan G. , Jain Rakesh K. , Fukumura Dai
Published: April 2023

Effects of VEGFR-1 signaling ablation on body weight gain, immune cell infiltration and vasculature in adipose tissues during obesity.
Supplementary Figure 5 from NDUFA4L2 Fine-tunes Oxidative Stress in Hepatocellular Carcinoma
Authors: Lai Robin Kit-Ho , Xu Iris Ming-Jing , Chiu David Kung-Chun , Tse Aki Pui-Wah , Wei Larry Lai , Law Cheuk-Ting , Lee Derek , Wong Chun-Ming , Wong Maria Pik , Ng Irene Oi-Lin , Wong Carmen Chak-Lui
Published: April 2023

Figure S5. Knockdown of NDUFA4L2 increases mitochondrial membrane potential and ROS production in hypoxia.
Supplementary Figure 4 from NDUFA4L2 Fine-tunes Oxidative Stress in Hepatocellular Carcinoma
Authors: Lai Robin Kit-Ho , Xu Iris Ming-Jing , Chiu David Kung-Chun , Tse Aki Pui-Wah , Wei Larry Lai , Law Cheuk-Ting , Lee Derek , Wong Chun-Ming , Wong Maria Pik , Ng Irene Oi-Lin , Wong Carmen Chak-Lui
Published: April 2023

Figure S4. NDUFA4 is preferentially expressed under normoxia.
Supplemental Table 2 from AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma
Authors: Brand Toni M. , Iida Mari , Stein Andrew P. , Corrigan Kelsey L. , Braverman Cara M. , Coan John P. , Pearson Hannah E. , Bahrar Harsh , Fowler Tyler L. , Bednarz Bryan P. , Saha Sandeep , Yang David , Gill Parkash S. , Lingen Mark W. , Saloura Vassiliki , Villaflor Victoria M. , Salgia Ravi , Kimple Randall J. , Wheeler Deric L.
Published: April 2023

Supplemental Table 2. Clinical parameters and median progression-free survival in relation to AXL expression among patients with HNSCC
Supplementary Figure 3 from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity
Authors: Mangsbo Sara M. , Broos Sissela , Fletcher Erika , Veitonmäki Niina , Furebring Christina , Dahlén Eva , Norlén Per , Lindstedt Malin , Tötterman Thomas H. , Ellmark Peter
Published: April 2023

Supplementary Figure 3. Anti-tumor effect on MB49 tumors. ADC-1013 generates a significant anti-tumor effect on CD40 negative MB49 cells in hCD40tg mice. Treatment with ADC-1013 or isotype control was performed on day 7 and 10 post tumor inoculation. Increasing doses of ADC-1013 were administred peritumorally in 100 ul PBS and the individual tumor growth curves are displayed.
Supplementary Table S1 from Inactivation of the p53–KLF4–CEBPA Axis in Acute Myeloid Leukemia
Authors: Seipel Katja , Marques Miguel Teixera , Bozzini Marie-Ange , Meinken Christina , Mueller Beatrice U. , Pabst Thomas
Published: April 2023

Table S1: Molecular and karyotype analysis of AML patients
Supplementary Figure S2 from Inactivation of the p53–KLF4–CEBPA Axis in Acute Myeloid Leukemia
Authors: Seipel Katja , Marques Miguel Teixera , Bozzini Marie-Ange , Meinken Christina , Mueller Beatrice U. , Pabst Thomas
Published: April 2023

Fig. S2 Sensitivity of AML cells to conventional induction treatment and small molecule p53 activators.
Supplementary Table 1 from Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate
Authors: Attard Gerhardt , de Bono Johann S. , Logothetis Christopher J. , Fizazi Karim , Mukherjee Som D. , Joshua Anthony M. , Schrijvers Dirk , van den Eertwegh Alfons J.M. , Li Weimin , Molina Arturo , Griffin Thomas W. , Kheoh Thian , Ricci Deborah S. , Zelinsky Kathy , Rathkopf Dana E. , Scher Howard I. , Ryan Charles J.
Published: April 2023

Supplementary Table 1. Demographics and baseline characteristics by ERG class
Supplemental Table S3 from Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use
Authors: Srivastava Apurva K. , Jaganathan Soumya , Stephen Laurie , Hollingshead Melinda G. , Layhee Adam , Damour Eric , Govindharajulu Jeevan Prasaad , Donohue Jennifer , Esposito Dominic , Mapes James P. , Kinders Robert J. , Takebe Naoko , Tomaszewski Joseph E. , Kummar Shivaani , Doroshow James H. , Parchment Ralph E.
Published: April 2023

This file contains supplemental Table S3: Fitness-for-purpose clinical utility-Intratumoral biological variability
Supplemental Figure S3 from Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use
Authors: Srivastava Apurva K. , Jaganathan Soumya , Stephen Laurie , Hollingshead Melinda G. , Layhee Adam , Damour Eric , Govindharajulu Jeevan Prasaad , Donohue Jennifer , Esposito Dominic , Mapes James P. , Kinders Robert J. , Takebe Naoko , Tomaszewski Joseph E. , Kummar Shivaani , Doroshow James H. , Parchment Ralph E.
Published: April 2023

This file contains supplemental Figure S3: Storage stability of analytes
Supplementary Figure 5 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
Authors: Ohue Yoshihiro , Kurose Koji , Mizote Yu , Matsumoto Hirofumi , Nishio Yumi , Isobe Midori , Fukuda Minoru , Uenaka Akiko , Oka Mikio , Nakayama Eiichi
Published: April 2023

OS of the advanced adenocarcinoma patients with EGFRwt or EGFRmt tumors (A), and with XAGE1 (GAGED2a) antigen-positive EGFRwt or EGFRmt tumors and antibody, and XAGE1 (GAGED2a) antigen-negative EGFRmt tumors (B).
Supplementary Figure 4 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
Authors: Ohue Yoshihiro , Kurose Koji , Mizote Yu , Matsumoto Hirofumi , Nishio Yumi , Isobe Midori , Fukuda Minoru , Uenaka Akiko , Oka Mikio , Nakayama Eiichi
Published: April 2023

Correlation of OS with XAGE1 (GAGED2a) antibody titer in patients with XAGE1 (GAGED2a) antigen-positive tumors.
Supplementary Figure 3 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
Authors: Ohue Yoshihiro , Kurose Koji , Mizote Yu , Matsumoto Hirofumi , Nishio Yumi , Isobe Midori , Fukuda Minoru , Uenaka Akiko , Oka Mikio , Nakayama Eiichi
Published: April 2023

Representative results of analyses of CD4 (A) and CD8 (B) T cells expressing T cell activation and inhibitory molecules in PBMCs from an XAGE1 (GAGED2a) antibody-positive patient, KLU456 by FACS.
Supplementary Figure 1 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
Authors: Ohue Yoshihiro , Kurose Koji , Mizote Yu , Matsumoto Hirofumi , Nishio Yumi , Isobe Midori , Fukuda Minoru , Uenaka Akiko , Oka Mikio , Nakayama Eiichi
Published: April 2023

ICS of CD4 and CD8 T cells reactive against XAGE1 (GAGED2a).
Supplementary Figure 1 from Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin
Authors: Dalva-Aydemir Sevim , Bajpai Richa , Martinez Maylyn , Adekola Kehinde U.A. , Kandela Irawati , Wei Changyong , Singhal Seema , Koblinski Jennifer E. , Raje Noopur S. , Rosen Steven T. , Shanmugam Mala
Published: April 2023

Supplementary Figure 1. Combination of ritonavir and metformin is growth inhibitory in solid tumors such as breast and ovarian cancers. Breast (A) ovarian (B) cancer cell lines were cultured in the presence of 20µM ritonavir, and/or increasing concentrations of metformin for 72 hours. Impact of treatments on cell proliferation was evaluated by an MTS assay. Doxorubicin (10uM) was used as a positive control.
Figure Legend and Supplementary Figure 1 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma
Authors: Pham Christina D. , Flores Catherine , Yang Changlin , Pinheiro Elaine M. , Yearley Jennifer H. , Sayour Elias J. , Pei Yanxin , Moore Colin , McLendon Roger E. , Huang Jianping , Sampson John H. , Wechsler-Reya Robert , Mitchell Duane A.
Published: April 2023

Orthotopically transplanted tumors are uniformly lethal at determined minimum tumorigenic dose. (A) Tumors arising from Patched1 heterozygous (Ptch1+/-) mice and immune deficient NOD scid gamma (NSG) mice implanted with retrovirally transduced cerebellar neural stem cells (NSC) were serially passaged via stereotactic implantation in the cerebellum of immunocompetent C57BL/6 hosts. Animals were implanted with varying numbers of tumor cells to determine the minimum dose required to induce 100% lethality in tumor-bearing mice within one month. Stereotactic implantation of (B) 1 x 103 NSC MB tumor cells and (C) 1.25 x 105 Ptch1 MB cells were determined as the minimum tumorigenic dose carried forth in subsequent animal studies.
Supplementary Figure 1 from Topical Application of a Mucoadhesive Freeze-Dried Black Raspberry Gel Induces Clinical and Histologic Regression and Reduces Loss of Heterozygosity Events in Premalignant Oral Intraepithelial Lesions: Results from a Multicentered, Placebo-Controlled Clinical Trial
Authors: Mallery Susan R. , Tong Meng , Shumway Brian S. , Curran Alice E. , Larsen Peter E. , Ness Gregory M. , Kennedy Kelly S. , Blakey George H. , Kushner George M. , Vickers Aaron M. , Han Brian , Pei Ping , Stoner Gary D.
Published: April 2023

PDF file - 1911KB, Immunoblot analyses of proteins associated with either keratinocyte differentiation (TGase 1, Involucrin, Loricrin, Cytokeratin 10/13) or local enteric recycling (UDP-Glc DH, UGT1A) in biopsy tissues of clinical trial participants. As not all OIN lesions had sufficient size to obtain tissue for Western analyses, only samples from the larger OIN lesions are represented. We have previously confirmed that these enzymes of interest reside almost exclusively in the epithelia. Pan cytokeratin was therefore used as the protein loading control.
Supplementary Figure Legends from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo
Authors: Herman Sarah E.M. , Mustafa Rashida Z. , Jones Jade , Wong Deanna H. , Farooqui Mohammed , Wiestner Adrian
Published: April 2023

Supplementary Figure Legends for Supplementary Figures S1-4
Supplemental Figure S7 from 18F-FAZA PET Imaging Response Tracks the Reoxygenation of Tumors in Mice upon Treatment with the Mitochondrial Complex I Inhibitor BAY 87-2243
Authors: Chang Edwin , Liu Hongguang , Unterschemmann Kerstin , Ellinghaus Peter , Liu Shuanglong , Gekeler Volker , Cheng Zhen , Berndorff Dietmar , Gambhir Sanjiv S.
Published: April 2023

Supplemental Figure S7. Dose-dependent effect of BAY 87-243 (1 and 9 mg/kg) on (A) 18F-FAZA uptake and (B) tumor volume for H460 xenografts of nude, murine models. For (A), *- p<0.001 for 2-way ANOVA of vehicle vs. BAY 87-2243, n=6 tumors and for (B) *-P<0.01 for 2-way ANOVA of vehicle vs. BAY 87-2243, n=6 tumors.
Supplementary Figure 4 from Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models
Authors: Francis David M. , Huang Shyhmin , Armstrong Eric A. , Werner Lauryn R. , Hullett Craig , Li Chunrong , Morris Zachary S. , Swick Adam D. , Kragh Michael , Lantto Johan , Kimple Randall J. , Harari Paul M.
Published: April 2023

Body weight of animals during xenograft experiements.
Supplementary Figure 3 from Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models
Authors: Francis David M. , Huang Shyhmin , Armstrong Eric A. , Werner Lauryn R. , Hullett Craig , Li Chunrong , Morris Zachary S. , Swick Adam D. , Kragh Michael , Lantto Johan , Kimple Randall J. , Harari Paul M.
Published: April 2023

Additional effect of Pan-HER and radiation on programmed cell death
Supplementary Figure 3 from Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice
Authors: Kim Sun-Jin , Lee Ho Jeong , Kim Mark Seungwook , Choi Hyun Jin , He Junqin , Wu Qiuyu , Aldape Kenneth , Weinberg Jeffrey S. , Yung W.K. Alfred , Conrad Charles A. , Langley Robert R. , Lehembre François , Regenass Urs , Fidler Isaiah J.
Published: April 2023

Supplementary Figure 3. Combination therapy with macitentan and TMZ produces durable responses in mice with established LN-229 glioblastomas.
Supplementary Figure 1 from Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice
Authors: Kim Sun-Jin , Lee Ho Jeong , Kim Mark Seungwook , Choi Hyun Jin , He Junqin , Wu Qiuyu , Aldape Kenneth , Weinberg Jeffrey S. , Yung W.K. Alfred , Conrad Charles A. , Langley Robert R. , Lehembre François , Regenass Urs , Fidler Isaiah J.
Published: April 2023

Supplementary Figure 1. Combination therapy with macitentan and TMZ leads to regression of established LN-229 glioblastomas.
Supplemental Table 5 from An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors
Authors: Bikos Vasilis , Karypidou Maria , Stalika Evangelia , Baliakas Panagiotis , Xochelli Aliki , Sutton Lesley-Ann , Papadopoulos George , Agathangelidis Andreas , Papadopoulou Evdoxia , Davis Zadie , Algara Patricia , Kanellis George , Traverse-Glehen Alexandra , Mollejo Manuela , Anagnostopoulos Achilles , Ponzoni Maurilio , Gonzalez David , Pospisilova Sarka , Matutes Estella , Piris Miguel Angel , Papadaki Theodora , Ghia Paolo , Rosenquist Richard , Oscier David , Darzentas Nikos , Tzovaras Dimitrios , Belessi Chrysoula , Hadzidimitriou Anastasia , Stamatopoulos Kostas
Published: April 2023

Recurrent amino acid replacements. Counts and distribution per IGHV gene and V-subregion. Respective physicochemical characteristics of the substitutions
Supplementary Figure Legend from EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs
Authors: Kobayashi Yoshihisa , Togashi Yosuke , Yatabe Yasushi , Mizuuchi Hiroshi , Jangchul Park , Kondo Chiaki , Shimoji Masaki , Sato Katsuaki , Suda Kenichi , Tomizawa Kenji , Takemoto Toshiki , Hida Toyoaki , Nishio Kazuto , Mitsudomi Tetsuya
Published: April 2023

Legend for supplementary figure 1.
Supplemental Figure 1 from Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8+ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFNγ
Authors: Soong Ruey-Shyang , Song Liwen , Trieu Janson , Knoff Jayne , He Liangmei , Tsai Ya-Chea , Huh Warner , Chang Yung-Nien , Cheng Wen-Fang , Roden Richard B.S. , Wu T.-C. , Trimble Cornelia L. , Hung Chien-Fu
Published: April 2023

Supplemental Figure 1. E7-specific T cells efficiently migrated from circulation to the genital tract following imiquimod application
SSupplementary Figure 1 from Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8+ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFNγ
Authors: Soong Ruey-Shyang , Song Liwen , Trieu Janson , Knoff Jayne , He Liangmei , Tsai Ya-Chea , Huh Warner , Chang Yung-Nien , Cheng Wen-Fang , Roden Richard B.S. , Wu T.-C. , Trimble Cornelia L. , Hung Chien-Fu
Published: April 2023

PDF file - 70K, E7-specific T cells efficiently migrated from circulation to the genital tract following imiquimod application.
Figure S3 from DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas
Authors: Malouf Gabriel G. , Su Xiaoping , Zhang Jianping , Creighton Chad J. , Ho Thai H. , Lu Yue , Raynal Noël J.-M. , Karam Jose A. , Tamboli Pheroze , Allanick Frederick , Mouawad Roger , Spano Jean-Philippe , Khayat David , Wood Christopher G. , Jelinek Jaroslav , Tannir Nizar M.
Published: April 2023

A) Kaplan-Meier curves according to the 56 genes epi-signature in a training dataset of patients with clear-cell renal cell carcinomas from The Cancer Genome Atlas (TCGA) dataset. B) Kaplan-Meier curves according to the 56 genes epi-signature in a validation dataset of patients with clear-cell renal cell carcinomas from The Cancer Genome Atlas (TCGA) dataset.
Figure S1 from DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas
Authors: Malouf Gabriel G. , Su Xiaoping , Zhang Jianping , Creighton Chad J. , Ho Thai H. , Lu Yue , Raynal Noël J.-M. , Karam Jose A. , Tamboli Pheroze , Allanick Frederick , Mouawad Roger , Spano Jean-Philippe , Khayat David , Wood Christopher G. , Jelinek Jaroslav , Tannir Nizar M.
Published: April 2023

A) Box-plot for average gene expression of promoters located in CpG islands according to their methylation levels. B) Box-plot for average gene expression of promoters located outside CpG islands according to their methylation levels. Note that unmethylated promoters show the highest expression levels.
Supplementary Materials and Methods, Figure Legends from Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models
Authors: Meetze Kristan , Vincent Sylvie , Tyler Steven , Mazsa Elizabeth K. , Delpero Andrea R. , Bottega Steve , McIntosh Donna , Nicoletti Richard , Winston William M. , Weiler Solly , Feng Bin , Gyuris Jeno , Weng Zhigang
Published: April 2023

Supplementary Materials and Methods
Supplemental Figure S1 from DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia
Authors: Sehgal Alison R. , Gimotty Phyllis A. , Zhao Jianhua , Hsu Jing-Mei , Daber Robert , Morrissette Jennifer D. , Luger Selina , Loren Alison W. , Carroll Martin
Published: April 2023

Supplemental Figure S1. Patient flow diagram
Table S4 from Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIB/C Melanoma Patients with BRAFV600 Mutations
Authors: Bucheit Amanda D. , Chen Guo , Siroy Alan , Tetzlaff Michael , Broaddus Russell , Milton Denai , Fox Patricia , Bassett Roland , Hwu Patrick , Gershenwald Jeffrey E. , Lazar Alexander J. , Davies Michael A.
Published: April 2023

Table S4. Clinical outcomes by PTEN status in patients without BRAF V600 or NRAS mutations
Supplemental Figure 2. from NOTCH1 and SOX10 are Essential for Proliferation and Radiation Resistance of Cancer Stem–Like Cells in Adenoid Cystic Carcinoma
Authors: Panaccione Alex , Chang Michael T. , Carbone Beatrice E. , Guo Yan , Moskaluk Christopher A. , Virk Renu K. , Chiriboga Luis , Prasad Manju L. , Judson Benjamin , Mehra Saral , Yarbrough Wendell G. , Ivanov Sergey V.
Published: April 2023

FACS analysis of Accx11 cells stained with PE-conjugated CD133 antibody. CD133+ cells (red) comprise ~12.4% of the bulk population.
Supplementary Figures S1-3 from SIRT1/PGC1α-Dependent Increase in Oxidative Phosphorylation Supports Chemotherapy Resistance of Colon Cancer
Authors: Vellinga Thomas T. , Borovski Tijana , de Boer Vincent C.J. , Fatrai Szabolcs , van Schelven Susanne , Trumpi Kari , Verheem Andre , Snoeren Nikol , Emmink Benjamin L. , Koster Jan , Rinkes Inne H.M. Borel , Kranenburg Onno
Published: April 2023

Supplementary Figures S1-3. Supplementary figure S1 Cytochrome c oxidase (COX IV) is highly expressed in chemotherapy-treated liver metastases Supplementary figure S2 Expression changes of glycolytic and OXPHOS genes in response to chemotherapy. Supplementary figure S3 Oxygen consumption rates of colonospheres treated with chemotherapy +/- nicotinamide
Supplementary Materials and Methods, Figure Legends from DUSP1 Expression Induced by HDAC1 Inhibition Mediates Gefitinib Sensitivity in Non–Small Cell Lung Cancers
Authors: Lin Yun-Chieh , Lin Yu-Chin , Shih Jin-Yuan , Huang Wei-Jan , Chao Shi-Wei , Chang Yih-Leong , Chen Ching-Chow
Published: April 2023

Supplementary Materials and Methods includes preparation of WJ-26210-2 compound, materials, in vitro HDAC activity assay, immunoblotting, immunoprecipitation, immunofluorescence and immunohistochemistry, RT-PCR and real-time quantitative PCR (Q-PCR), ChIP-qPCR assay, plasmid transfection and lentivirus infection, cell proliferation and colony formation assays. And the legend of Supplementary Figures 1-6.
Supplementary Figure 1 from Curing Mice with Large Tumors by Locally Delivering Combinations of Immunomodulatory Antibodies
Authors: Dai Min , Yip Yuen Yee , Hellstrom Ingegerd , Hellstrom Karl Erik
Published: April 2023

Lymphocyte components of mice transplanted with tumor cells.
supplemental figure legend from Evaluating Acetate Metabolism for Imaging and Targeting in Multiple Myeloma
Authors: Fontana Francesca , Ge Xia , Su Xinming , Hathi Deep , Xiang Jingyu , Cenci Simone , Civitelli Roberto , Shoghi Kooresh I. , Akers Walter J. , D'avignon Andre , Weilbaecher Katherine N. , Shokeen Monica
Published: April 2023

supplemental figure legend
Supplementary References from Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies
Authors: Hu Wenyue , Sung Tae , Jessen Bart A. , Thibault Stephane , Finkelstein Martin B. , Khan Nasir K. , Sacaan Aida I.
Published: April 2023

Supplementary references are listed for supplementary table S1.
Supplementary Table 2 from Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer
Authors: Tucker Douglass W. , Getchell Christopher R. , McCarthy Eric T. , Ohman Anders W. , Sasamoto Naoko , Xu Shuyun , Ko Joo Yeon , Gupta Mamta , Shafrir Amy , Medina Jamie E. , Lee Jonathan J. , MacDonald Lauren A. , Malik Ammara , Hasselblatt Kathleen T , Li Wenjing , Zhang Hong , Kaplan Samuel J. , Murphy George F. , Hirsch Michelle S. , Liu Joyce F. , Matulonis Ursula A. , Terry Kathryn L. , Lian Christine G. , Dinulescu Daniela M.
Published: April 2023

Characteristics of HGSOC cases with platinum relapse data included in the BWH TMA
Supplementary Figures from Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy
Authors: Skarzynski Martin , Niemann Carsten U. , Lee Yuh Shan , Martyr Sabrina , Maric Irina , Salem Dalia , Stetler-Stevenson Maryalice , Marti Gerald E. , Calvo Katherine R. , Yuan Constance , Valdez Janet , Soto Susan , Farooqui Mohammed Z.H. , Herman Sarah E.M. , Wiestner Adrian
Published: April 2023

Supplementary Figure 1. Uniform CD20 loss from the surface of primary CLL cells after in vivo exposure to ibrutinib. Supplementary Figure 2. Loss of CD20 on ibrutinib and basal CD20 expression levels do not correlate with high risk prognostic factors. Supplementary Figure 3. Selective NF-κB inhibitor diminishes CD20 cell surface expression. Supplementary Figure 4. Complement regulatory proteins membrane cofactor protein and protectin are not consistently inhibited by ibrutinib.
Supplementary Figure 5 from Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer
Authors: Tucker Douglass W. , Getchell Christopher R. , McCarthy Eric T. , Ohman Anders W. , Sasamoto Naoko , Xu Shuyun , Ko Joo Yeon , Gupta Mamta , Shafrir Amy , Medina Jamie E. , Lee Jonathan J. , MacDonald Lauren A. , Malik Ammara , Hasselblatt Kathleen T , Li Wenjing , Zhang Hong , Kaplan Samuel J. , Murphy George F. , Hirsch Michelle S. , Liu Joyce F. , Matulonis Ursula A. , Terry Kathryn L. , Lian Christine G. , Dinulescu Daniela M.
Published: April 2023

In vivo IHC scores quantified
Supplementary Figure 2 from Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer
Authors: Tucker Douglass W. , Getchell Christopher R. , McCarthy Eric T. , Ohman Anders W. , Sasamoto Naoko , Xu Shuyun , Ko Joo Yeon , Gupta Mamta , Shafrir Amy , Medina Jamie E. , Lee Jonathan J. , MacDonald Lauren A. , Malik Ammara , Hasselblatt Kathleen T , Li Wenjing , Zhang Hong , Kaplan Samuel J. , Murphy George F. , Hirsch Michelle S. , Liu Joyce F. , Matulonis Ursula A. , Terry Kathryn L. , Lian Christine G. , Dinulescu Daniela M.
Published: April 2023

Immunofluorescence studies on patient tumor ascites, quantification of 5-hmC from patient ascites by dot blot, 5-hmC measured with mass spectrometry
supplemental specical presentations from Phase I Study of Chimeric Antigen Receptor–Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers
Authors: Guo Yelei , Feng Kaichao , Liu Yang , Wu Zhiqiang , Dai Hanren , Yang Qingming , Wang Yao , Jia Hejin , Han Weidong
Published: April 2023

specical presentations of three patients treated with CART-EGFR monotherapy
supplemental figures from Phase I Study of Chimeric Antigen Receptor–Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers
Authors: Guo Yelei , Feng Kaichao , Liu Yang , Wu Zhiqiang , Dai Hanren , Yang Qingming , Wang Yao , Jia Hejin , Han Weidong
Published: April 2023

Supplemental Figure 1. Consort diagram. Supplemental Figure 2. Characteristics of CART-EGFR cell products. Supplemental Figure 3. Correlations between lymphocyte counts and clinical response and transgene copies. Supplemental Figure 4. Changes in all patients' serum cytokine levels before and at serial time points after CART-EGFR cell infusion. Supplemental Figure 5. PET-CT scan images (patient No. 1) 3, 6 and 22 months after the CART-RGFR cell treatment. Supplemental Figure 6. A. Using linear regression analysis, it was determined that the number of CAR transgene copies after CART-EGFR cell infusion had no correlation with the dose of infused CART-EGFR cells. Supplemental Figure 7. CART-EGFR cell monotherapy in three special patients (SPs) with BTCs.
Figure S2 from NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
Authors: Charych Deborah H. , Hoch Ute , Langowski John L. , Lee Steve R. , Addepalli Murali K. , Kirk Peter B. , Sheng Dawei , Liu Xiaofeng , Sims Paul W. , VanderVeen Laurie A. , Ali Cherie F. , Chang Thomas K. , Konakova Marina , Pena Rhoneil L. , Kanhere Rupesh S. , Kirksey Yolanda M. , Ji Chunmei , Wang Yujun , Huang Jicai , Sweeney Theresa D. , Kantak Seema S. , Doberstein Stephen K.
Published: April 2023

Binding curves from surface plasmon resonance studies of purified active 1-PEG-IL-2 released from NKTR-214 binding to IL-2Rαβ and IL-2Rβ
Supporting Information from Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer
Authors: Arqués Oriol , Chicote Irene , Puig Isabel , Tenbaum Stephan P. , Argilés Guillem , Dienstmann Rodrigo , Fernández Natalia , Caratù Ginevra , Matito Judit , Silberschmidt Daniel , Rodon Jordi , Landolfi Stefania , Prat Aleix , Espín Eloy , Charco Ramón , Nuciforo Paolo , Vivancos Ana , Shao Wenlin , Tabernero Josep , Palmer Héctor G.
Published: April 2023

Supporting Information. Supplementary methods to complete the information for gene expression, genotyping, immunohistochemistry evaluation criteria and protein extraction. The file also contains legends for supplementary figures S1-S11 and supplementary tables S1-S15.